Abstract:

Objective Human serum albumin ⁃ sorafenib nanoparticles（HSA ⁃ SRF ⁃NPs）were prepared and then their anti⁃hepatic tumor activity was evaluated in vitro. Methods HSA⁃SRF⁃NPs were prepared by chem⁃ ical cross⁃linking method，and their characterization was studied by a laser granulometer and a transmission elec⁃ tron microscope. The drug loading volume and encapsulation rate were calculated. Accumulation of nanoparticles in BEL ⁃ 7402 cells was observed by a fluorescence microscope，the proliferation inhibition of BEL ⁃ 7402 cells by nanoparticles was evaluated by the IncuCyte ZOOM system，and the proapoptotic effect of HSA⁃SRF⁃NPs on BEL⁃ 7402 cells was detected by flow cytometry and Western blotting. Results The particle size of HSA⁃SRF⁃NPs was （75.8 ± 2.6）nm and the Zeta potential was（-19.00 ± 1.02）mV，and the drug loading volume and encapsulation rate were（4.23 ± 0.03）% and（92.52 ± 2.40）% ，respectively. HSA ⁃ SRF ⁃ NPs could accumulate in BEL ⁃ 7402 cells，the proliferation inhibition and proapoptotic effect of HSA⁃SRF⁃NPs were significantly stronger than those of sorafenib. Conclusions HSA⁃SRF⁃NPs possess better properties，which can significantly improve the anti⁃hepatic tumor activity of sorafenib. They have potential prospect of clinical applications. 

Key words:

sorafenib, human serum albumin, nanoparticles, liver cancer